TrialHeadache2021

STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD

Timothy R Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.